SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 118 filers reported holding SAREPTA THERAPEUTICS INC in Q1 2014. The put-call ratio across all filers is 0.89 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $248,625,166 | +31.5% | 1,573,577 | +7.7% | 0.11% | +27.3% |
Q1 2024 | $189,073,093 | +32.9% | 1,460,475 | -1.0% | 0.09% | +20.5% |
Q4 2023 | $142,230,587 | +9.5% | 1,474,962 | +37.7% | 0.07% | -13.1% |
Q3 2023 | $129,840,924 | +2.4% | 1,071,118 | -3.2% | 0.08% | +25.4% |
Q2 2023 | $126,739,513 | -8.1% | 1,106,702 | +10.7% | 0.07% | -13.0% |
Q1 2023 | $137,846,677 | +13.2% | 1,000,121 | +6.4% | 0.08% | +10.0% |
Q4 2022 | $121,816,603 | +47.5% | 940,088 | +25.8% | 0.07% | +40.0% |
Q3 2022 | $82,588,000 | +60.1% | 747,135 | +8.6% | 0.05% | +72.4% |
Q2 2022 | $51,579,000 | -13.2% | 688,093 | -9.5% | 0.03% | +3.6% |
Q1 2022 | $59,429,000 | -9.0% | 760,731 | +4.9% | 0.03% | -3.4% |
Q4 2021 | $65,286,000 | +50.9% | 725,009 | +55.0% | 0.03% | +38.1% |
Q3 2021 | $43,267,000 | +24.1% | 467,865 | +4.3% | 0.02% | +23.5% |
Q2 2021 | $34,875,000 | -8.2% | 448,619 | -12.0% | 0.02% | -15.0% |
Q1 2021 | $37,989,000 | -56.8% | 509,715 | -1.2% | 0.02% | -63.0% |
Q4 2020 | $87,926,000 | +22.2% | 515,722 | +0.7% | 0.05% | +10.2% |
Q3 2020 | $71,941,000 | -38.3% | 512,286 | -29.6% | 0.05% | -44.9% |
Q2 2020 | $116,671,000 | +37.6% | 727,652 | -16.0% | 0.09% | +17.1% |
Q1 2020 | $84,780,000 | -34.1% | 866,686 | -13.1% | 0.08% | -9.5% |
Q4 2019 | $128,700,000 | +103.2% | 997,391 | +18.6% | 0.08% | +90.9% |
Q3 2019 | $63,339,000 | -55.2% | 840,975 | -9.6% | 0.04% | -47.0% |
Q2 2019 | $141,345,000 | +14.2% | 930,224 | -10.4% | 0.08% | +12.2% |
Q1 2019 | $123,751,000 | +8.8% | 1,038,300 | -0.4% | 0.07% | -8.6% |
Q4 2018 | $113,781,000 | -54.5% | 1,042,649 | -32.7% | 0.08% | +11.0% |
Q3 2018 | $250,145,000 | +3.7% | 1,548,806 | -15.1% | 0.07% | +5.8% |
Q2 2018 | $241,250,000 | +232.0% | 1,825,190 | +86.1% | 0.07% | +97.1% |
Q1 2018 | $72,671,000 | +1.6% | 980,872 | -23.7% | 0.04% | -23.9% |
Q4 2017 | $71,501,000 | +8.6% | 1,285,146 | -11.5% | 0.05% | +2.2% |
Q3 2017 | $65,869,000 | +302.1% | 1,452,239 | +198.8% | 0.04% | +275.0% |
Q2 2017 | $16,380,000 | +109.1% | 486,029 | +83.5% | 0.01% | +100.0% |
Q1 2017 | $7,835,000 | -9.1% | 264,810 | -15.8% | 0.01% | -14.3% |
Q4 2016 | $8,622,000 | -57.7% | 314,364 | -5.3% | 0.01% | -50.0% |
Q3 2016 | $20,394,000 | +140.2% | 332,130 | -25.4% | 0.01% | +133.3% |
Q2 2016 | $8,490,000 | -34.1% | 445,308 | -32.6% | 0.01% | -40.0% |
Q1 2016 | $12,888,000 | +4.6% | 660,365 | +106.7% | 0.01% | +11.1% |
Q4 2015 | $12,320,000 | +22.8% | 319,408 | +2.2% | 0.01% | +12.5% |
Q3 2015 | $10,029,000 | +69.9% | 312,390 | +61.0% | 0.01% | +100.0% |
Q2 2015 | $5,903,000 | +97.8% | 194,047 | -13.8% | 0.00% | +100.0% |
Q1 2015 | $2,985,000 | +35.4% | 225,013 | +47.6% | 0.00% | +100.0% |
Q4 2014 | $2,205,000 | +28.5% | 152,484 | +87.2% | 0.00% | 0.0% |
Q3 2014 | $1,716,000 | -28.2% | 81,459 | +1.5% | 0.00% | -50.0% |
Q2 2014 | $2,389,000 | -0.3% | 80,248 | -19.6% | 0.00% | 0.0% |
Q1 2014 | $2,396,000 | +24.4% | 99,814 | +5.5% | 0.00% | +100.0% |
Q4 2013 | $1,926,000 | -75.0% | 94,618 | -41.9% | 0.00% | -83.3% |
Q3 2013 | $7,692,000 | – | 162,909 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Evolutionary Tree Capital Management, LLC | 68,937 | $5,138,000 | 3.04% |
Avoro Capital Advisors LLC | 2,150,000 | $160,240,000 | 2.77% |
Casdin Capital, LLC | 550,000 | $40,992,000 | 1.22% |
TOBAM | 371,107 | $27,659,000 | 1.18% |
Ikarian Capital, LLC | 455,900 | $33,978,000 | 1.14% |
Eventide Asset Management | 697,156 | $51,959,000 | 0.77% |
FOX RUN MANAGEMENT, L.L.C. | 4,902 | $365,000 | 0.66% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 31,500 | $2,348,000 | 0.62% |
Sivik Global Healthcare LLC | 20,000 | $1,491,000 | 0.54% |
Rock Springs Capital Management LP | 328,750 | $24,502,000 | 0.54% |